PACB Q2 Deep Dive: Leadership Transition and SPRQ-Nx Rollout Shape Outlook

Genomics company Pacific Biosciences of California (NASDAQ:PACB) fell short of the market’s revenue expectations in Q2 CY2026, with sales falling 1.9% year on year to $39.01 million. Its non-GAAP loss of $0.14 per share was 10.4% below analysts’ consensus estimates.

Is now the time to buy PACB? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

PacBio’s second quarter was met with a negative market reaction, as sales and adjusted earnings per share both fell short of Wall Street’s expectations. Management attributed the underperformance to ongoing funding constraints in the U.S. academic and government sectors, as well as a transition period as customers validated the new SPRQ-Nx chemistry. CEO Mark Van Oene, newly appointed after Christian Henry’s departure, stated that “customer enthusiasm for SPRQ-Nx has remained strong since full launch,” but acknowledged that the pace of adoption and inventory dynamics weighed on quarterly results.

Looking ahead, PacBio’s management believes SPRQ-Nx adoption will drive higher consumable usage and improved economics, especially among clinical customers transitioning to routine production. Mark Van Oene emphasized that the company’s focus is on scaling clinical engagement globally and streamlining operations, while CFO James Gibson cautioned that persistent memory costs and a gradual ramp-up in SPRQ-Nx adoption remain headwinds. Management now expects cash flow breakeven to be reached in 2028, reflecting a more measured outlook as the company navigates a key technology transition and macro funding challenges.

Key Insights from Management’s Remarks

PacBio’s latest quarter was shaped by technology transition dynamics, a strategic leadership change, and regional funding pressures, with management highlighting several operational and commercial developments that influenced the results.

• Leadership transition: Christian Henry stepped down as CEO, with Mark Van Oene promoted to the role. Van Oene’s background in R&D and commercial operations is expected to guide PacBio through its next phase, emphasizing deeper clinical market engagement and streamlined execution.

• SPRQ-Nx rollout impact: The global launch of SPRQ-Nx, a new sequencing chemistry enabling higher throughput and multi-use SMRT Cells, was a central development this quarter. Customer feedback was positive, but the transition period resulted in customers working through existing inventory and validating workflows, which temporarily dampened consumables revenue growth.

• Clinical market momentum: Clinical customers represented a growing share of new system placements and consumables shipments, particularly in the EMEA region. Management cited a 67% year-over-year increase in clinical shipments and expects these accounts to move from pilot to production mode, fueling future growth.

• Regional funding constraints: U.S. academic and government funding uncertainties continued to pressure instrument sales, while Asia Pacific revenue declined as customers prepared for SPRQ-Nx adoption. EMEA remained a bright spot, showing strong demand and strategic multi-system placements linked to national genomics initiatives.

• Operational reorganization: PacBio initiated a targeted restructuring, integrating marketing with commercial operations and reducing management layers. This move is aimed at sharpening clinical focus and lowering operating expenses without impacting key R&D projects.

Drivers of Future Performance

PacBio’s forward guidance centers on the adoption curve for SPRQ-Nx chemistry, operational efficiency improvements, and ongoing challenges from elevated supply chain costs and market funding pressures.

• SPRQ-Nx adoption pace: Management expects SPRQ-Nx to be a major driver of consumables growth as more customers complete workflow validation and reorder at higher volumes. The transition to multi-use consumables is projected to improve cost-per-genome and expand addressable projects, but the adoption curve is expected to be gradual through the end of the year.

• Cost and margin headwinds: CFO James Gibson noted that temporary manufacturing transition costs, elevated compute and memory expenses, and strategic lower-priced system placements will pressure gross margins in the near term. While restructuring efforts should reduce expenses over time, management acknowledged that persistent supply chain costs are delaying gross margin recovery.

• Clinical and global expansion: The company is prioritizing clinical market penetration, especially in EMEA, and leveraging its technology’s validation in rare disease diagnostics to drive broader adoption. Management believes that scaling clinical and population genomics projects will be key to future revenue growth, but recognizes that capital spending constraints in the Americas and Asia Pacific may limit near-term upside.

Catalysts in Upcoming Quarters

In coming quarters, the StockStory team will closely monitor (1) the pace of SPRQ-Nx adoption and its impact on consumables growth, (2) progress in clinical and population-scale project expansion, particularly in EMEA and new customer segments, and (3) the company’s success in mitigating supply chain and manufacturing cost pressures. Operational execution in driving clinical engagement and expanding gross margins will also be key signposts for PacBio’s path forward.

PacBio currently trades at $1.17, down from $1.31 just before the earnings. Is there an opportunity in the stock? Find out in our full research report (it’s free).

Now Could Be The Perfect Time To Invest In These Stocks

ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.

Find out which 5 stocks it’s flagging this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+1,154% between June 2020 and June 2025). Find your next big winner with StockStory today.